Sepio Capital LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,604 shares of the company’s stock after selling 352 shares during the quarter. Sepio Capital LLC’s holdings in Novo Nordisk A/S were worth $3,655,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of NVO. Amundi Pioneer Asset Management Inc. bought a new stake in Novo Nordisk A/S during the first quarter valued at about $49,039,000. Jennison Associates LLC acquired a new stake in Novo Nordisk A/S in the first quarter worth about $33,951,000. Raymond James & Associates boosted its holdings in Novo Nordisk A/S by 83.8% in the first quarter. Raymond James & Associates now owns 1,174,105 shares of the company’s stock worth $61,418,000 after acquiring an additional 535,302 shares in the last quarter. Sphera Funds Management LTD. acquired a new stake in Novo Nordisk A/S in the first quarter worth about $20,924,000. Finally, Clearbridge Investments LLC boosted its holdings in Novo Nordisk A/S by 42.3% in the first quarter. Clearbridge Investments LLC now owns 1,160,942 shares of the company’s stock worth $60,729,000 after acquiring an additional 344,989 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.
Shares of Novo Nordisk A/S stock traded up $0.13 on Tuesday, reaching $52.30. 49,379 shares of the stock were exchanged, compared to its average volume of 1,455,540. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.06. Novo Nordisk A/S has a twelve month low of $41.23 and a twelve month high of $52.84. The firm has a market capitalization of $128.74 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 2.23 and a beta of 0.60. The business has a 50 day moving average price of $49.65 and a two-hundred day moving average price of $49.73.
The business also recently declared a Semi-Annual dividend, which will be paid on Tuesday, August 27th. Investors of record on Monday, August 19th will be given a dividend of $0.318 per share. The ex-dividend date of this dividend is Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is currently 25.40%.
NVO has been the subject of several recent analyst reports. Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price target for the company in a report on Tuesday, June 11th. Deutsche Bank downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price target for the company. in a report on Thursday, June 20th. UBS Group reissued a “buy” rating and issued a $355.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, June 19th. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, August 5th. Finally, Credit Suisse Group raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Monday, April 29th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $111.58.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Recommended Story: Technical Analysis of Stocks, How Can It Help
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.